RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
PharmaResearch Co Stock

PharmaResearch Co Debt 2024

PharmaResearch Co Debt

-32,971.46 KRW

Ticker

214450.KQ

ISIN

KR7214450009

In 2024, PharmaResearch Co's total debt was -32,971.46 KRW, a 434.98% change from the -6,163.09 KRW total debt recorded in the previous year.

PharmaResearch Co Aktienanalyse

What does PharmaResearch Co do?

PharmaResearch Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding PharmaResearch Co's Debt Structure

PharmaResearch Co's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing PharmaResearch Co's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to PharmaResearch Co’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in PharmaResearch Co’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about PharmaResearch Co stock

What is the debt of PharmaResearch Co this year?

PharmaResearch Co has a debt level of -32,971.46 KRW this year.

What was the debt of PharmaResearch Co compared to the previous year?

The debt of PharmaResearch Co has increased by 434.98% compared to the previous year increased.

What are the consequences of high debt for investors in PharmaResearch Co?

High debt can pose a risk for investors of PharmaResearch Co, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of PharmaResearch Co?

Low debt means that PharmaResearch Co has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from PharmaResearch Co affect the company?

An increase in debt of PharmaResearch Co can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of PharmaResearch Co affect the company?

A reduction in debt of PharmaResearch Co can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of PharmaResearch Co?

Some factors that can influence the debt of PharmaResearch Co include investments, acquisitions, operating costs, and revenue development.

Why are the debts of PharmaResearch Co so important for investors?

The debts of PharmaResearch Co are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can PharmaResearch Co take to change the debt?

To change the debt, PharmaResearch Co can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does PharmaResearch Co pay?

Over the past 12 months, PharmaResearch Co paid a dividend of 950 KRW . This corresponds to a dividend yield of about 0.49 %. For the coming 12 months, PharmaResearch Co is expected to pay a dividend of 1,044.52 KRW.

What is the dividend yield of PharmaResearch Co?

The current dividend yield of PharmaResearch Co is 0.49 %.

When does PharmaResearch Co pay dividends?

PharmaResearch Co pays a quarterly dividend. This is distributed in the months of January, January, January, January.

How secure is the dividend of PharmaResearch Co?

PharmaResearch Co paid dividends every year for the past 12 years.

What is the dividend of PharmaResearch Co?

For the upcoming 12 months, dividends amounting to 1,044.52 KRW are expected. This corresponds to a dividend yield of 0.54 %.

In which sector is PharmaResearch Co located?

PharmaResearch Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von PharmaResearch Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of PharmaResearch Co from 4/18/2024 amounting to 950 KRW, you needed to have the stock in your portfolio before the ex-date on 12/27/2023.

When did PharmaResearch Co pay the last dividend?

The last dividend was paid out on 4/18/2024.

What was the dividend of PharmaResearch Co in the year 2023?

In the year 2023, PharmaResearch Co distributed 660 KRW as dividends.

In which currency does PharmaResearch Co pay out the dividend?

The dividends of PharmaResearch Co are distributed in KRW.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von PharmaResearch Co

Our stock analysis for PharmaResearch Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of PharmaResearch Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.